Genmab Looks Past Turnaround to Takeoff

Dow Jones
11/16

1026 GMT - Genmab's trio of positive late-stage clinical trials mean the Danish biotech company is moving away from a turnaround toward its takeoff, UBS analysts say in a research note. "Genmab has achieved something that is rarely seen in the pharma industry--a highly successful [research-and-development] turnaround," the analysts say. In October, the company reported three very strong late-stage data sets that justified its recent stock rally as each of the drugs has potential to generate more than $7 billion in annual revenue, according to UBS. "We think this is only the start," the analysts add. UBS raises its target price on Genmab to 4,900 Danish kroner from 3,100 kroner. Shares trade 2.4% higher at 3,532 kroner, having gained 74% since the start of 2026.

 

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10